Anika Therapeutics, Inc. (ANIK) Reports Q3 EPS of 22c
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $14.63 -2.53%
Revenue Growth %: +3.5%
Financial Fact:
Selling, general & administrative: 4.28M
Today's EPS Names:
DTGI, CRMT, STZ, More
Revenue Growth %: +3.5%
Financial Fact:
Selling, general & administrative: 4.28M
Today's EPS Names:
DTGI, CRMT, STZ, More
Join SI Premium – FREE
Anika Therapeutics, Inc. (NASDAQ: ANIK) reported Q3 EPS of $0.22, vs. the analyst estimate of $0.11. Revenue for the quarter came in at $18.5 million versus the consensus estimate of $15.1 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Constellation Brands (STZ) Tops Q1 EPS by 18c
- Corona-maker Constellation Brands beats estimates, shares jump 2%
- Trip.com Group (TCOM) Misses Q1 EPS by 41c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
